These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 38042816)

  • 1. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
    Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
    Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease.
    Han AL; Lee HK
    Metabolites; 2022 Jul; 12(7):. PubMed ID: 35888788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
    Chen J; Mao X; Deng M; Luo G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.
    Cai J; Lin C; Lai S; Liu Y; Liang M; Qin Y; Liang X; Tan A; Gao Y; Lu Z; Wu C; Huang S; Yang X; Zhang H; Kuang J; Mo Z
    Lipids Health Dis; 2021 Oct; 20(1):145. PubMed ID: 34706716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
    Liu Y; Liu S; Huang J; Zhu Y; Lin S
    J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities.
    Okada A; Yamada G; Kimura T; Hagiwara Y; Yamaguchi S; Kurakawa KI; Nangaku M; Yamauchi T; Matsuyama Y; Kadowaki T
    J Diabetes Investig; 2023 Mar; 14(3):463-478. PubMed ID: 36566480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
    Li H; Zhang Y; Luo H; Lin R
    Front Endocrinol (Lausanne); 2022; 13():977625. PubMed ID: 36407325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the clinical value of five noninvasive predictors of metabolic dysfunction-associated steatotic liver disease in Han Chinese adults.
    Ma X; Zou H; Zhan J; Gao J; Xie Y
    Eur J Gastroenterol Hepatol; 2024 Oct; 36(10):1209-1219. PubMed ID: 38973526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the appropriate cutoff points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease.
    Hosseini SA; Alipour M; Sarvandian S; Haghighat N; Bazyar H; Aghakhani L
    BMC Endocr Disord; 2024 Jun; 24(1):79. PubMed ID: 38834991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People.
    Otsubo N; Fukuda T; Cho G; Ishibashi F; Yamada T; Monzen K
    Intern Med; 2023 Aug; 62(16):2307-2319. PubMed ID: 36517035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome.
    Chen LD; Huang JF; Chen QS; Lin GF; Zeng HX; Lin XF; Lin XJ; Lin L; Lin QC
    Chin Med J (Engl); 2019 Nov; 132(22):2670-2676. PubMed ID: 31765354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: A retrospective case-control study.
    Liu J; Duan S; Wang C; Wang Y; Peng H; Niu Z; Yao S
    Front Endocrinol (Lausanne); 2022; 13():1035418. PubMed ID: 36531447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
    Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
    BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease.
    Han AL
    Diabetol Metab Syndr; 2022 Mar; 14(1):44. PubMed ID: 35317824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External validation and comparison of simple tools to screen for nonalcoholic fatty liver disease in Chinese community population.
    Zhang L; Zhang M; Wang M; Wang M; Zhang R; Wang H; Zhang W; Ding Y; Wang J
    Eur J Gastroenterol Hepatol; 2022 Aug; 34(8):865-872. PubMed ID: 35802528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction and Validation of Metabolic Dysfunction-Associated Fatty Liver Disease Using Fatty Liver-Related Indices in a Japanese Population.
    Moriyama K
    Metab Syndr Relat Disord; 2024 Apr; 22(3):190-198. PubMed ID: 38153394
    [No Abstract]   [Full Text] [Related]  

  • 18. Usefulness of Body Fat and Visceral Fat Determined by Bioimpedanciometry versus Body Mass Index and Waist Circumference in Predicting Elevated Values of Different Risk Scales for Non-Alcoholic Fatty Liver Disease.
    Gordito Soler M; López-González ÁA; Vallejos D; Martínez-Almoyna Rifá E; Vicente-Herrero MT; Ramírez-Manent JI
    Nutrients; 2024 Jul; 16(13):. PubMed ID: 38999907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese.
    Huang X; Xu M; Chen Y; Peng K; Huang Y; Wang P; Ding L; Lin L; Xu Y; Chen Y; Lu J; Wang W; Bi Y; Ning G
    Medicine (Baltimore); 2015 Oct; 94(40):e1682. PubMed ID: 26448014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.